| __timestamp | Eli Lilly and Company | Pfizer Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 14097000000 |
| Thursday, January 1, 2015 | 6533000000 | 14809000000 |
| Friday, January 1, 2016 | 6452000000 | 14837000000 |
| Sunday, January 1, 2017 | 6588100000 | 14784000000 |
| Monday, January 1, 2018 | 5975100000 | 14455000000 |
| Tuesday, January 1, 2019 | 6213800000 | 14350000000 |
| Wednesday, January 1, 2020 | 6121200000 | 11615000000 |
| Friday, January 1, 2021 | 6431600000 | 12703000000 |
| Saturday, January 1, 2022 | 6440400000 | 13677000000 |
| Sunday, January 1, 2023 | 6941200000 | 14771000000 |
| Monday, January 1, 2024 | 8593800000 | 14730000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Eli Lilly and Company and Pfizer Inc. have demonstrated distinct strategies in managing these costs. From 2014 to 2023, Pfizer consistently allocated more than double the SG&A expenses compared to Eli Lilly, peaking at approximately $14.8 billion in 2016. Meanwhile, Eli Lilly maintained a more conservative approach, with expenses hovering around $6.4 billion, except for a notable dip in 2018. This strategic difference highlights Pfizer's aggressive market expansion and Eli Lilly's focus on streamlined operations. As of 2023, both companies show a trend of increasing SG&A expenses, reflecting the industry's response to global challenges and opportunities. These insights offer a window into the financial strategies shaping the future of pharmaceuticals.
Eli Lilly and Company vs Intra-Cellular Therapies, Inc.: SG&A Expense Trends
Eli Lilly and Company or Insmed Incorporated: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Viatris Inc.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Sarepta Therapeutics, Inc.
Breaking Down SG&A Expenses: Eli Lilly and Company vs CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and ACADIA Pharmaceuticals Inc.
Eli Lilly and Company vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Comparing SG&A Expenses: Pfizer Inc. vs Gilead Sciences, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Pfizer Inc. or Bristol-Myers Squibb Company
SG&A Efficiency Analysis: Comparing Pfizer Inc. and Summit Therapeutics Inc.
Comparing SG&A Expenses: Pfizer Inc. vs Madrigal Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Pfizer Inc. and Iovance Biotherapeutics, Inc.